CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023

Rhea-AI Summary

CTI BioPharma Corp. (Nasdaq: CTIC) announced its participation in two key investor conferences in April 2023, aimed at discussing its novel targeted therapies for blood-related cancers. The company will engage in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 3:45 p.m. ET, and will present at the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 1:00 p.m. ET. Live and archived webcasts can be accessed through the CTI BioPharma website. CTI BioPharma is also noted for its FDA-approved product, VONJO® (pacritinib), which targets myelofibrosis patients with low platelet counts.

SEATTLE, Wash., April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that the management team will participate in two upcoming investor conferences in April 2023.

22^nd Annual Needham Virtual Healthcare Conference
Type: Fireside Chat
Tuesday, April 18, 2023
3:45 p.m. ET (12:45 p.m. PT)

Stifel 2023 Targeted Oncology Days (Virtual)
Type: Corporate Presentation
Wednesday, April 26, 2023
1:00 p.m. ET (10:00 a.m. PT)

A link to the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations.

About CTI BioPharma Corp.

CTI BioPharma is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2, ACVR1,­­ and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. For more information, please visit www.ctibiopharma.com.

VONJO® is a registered trademark of CTI BioPharma Corp.

Investor Relations and Media Contacts:

Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-participate-in-two-upcoming-investor-conferences-in-april-2023-301796072.html

SOURCE CTI BioPharma Corp.

FAQ

When will CTI BioPharma participate in the Needham Virtual Healthcare Conference?

CTI BioPharma will participate in the Needham Virtual Healthcare Conference on April 18, 2023, at 3:45 p.m. ET.

What is the date of CTI BioPharma's presentation at the Stifel 2023 Targeted Oncology Days?

CTI BioPharma's presentation at the Stifel 2023 Targeted Oncology Days will occur on April 26, 2023, at 1:00 p.m. ET.

How can I access the webcasts for CTI BioPharma's investor conferences?

The live and archived webcasts for CTI BioPharma's investor conferences can be accessed on their website under the Investors & Media section.

What is VONJO and its purpose?

VONJO® (pacritinib) is an FDA-approved drug by CTI BioPharma for treating adults with intermediate- or high-risk myelofibrosis who have a platelet count below 50 × 10^9/L.

Is CTI BioPharma conducting any studies related to VONJO?

Yes, CTI BioPharma is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia.